A Phase II Randomized Trial (GO27827) of First-Line FOLFOX Plus Bevacizumab with or Without the MET Inhibitor Onartuzumab in Patients with Metastatic Colorectal Cancer.
Saved in:
| Title: | A Phase II Randomized Trial (GO27827) of First-Line FOLFOX Plus Bevacizumab with or Without the MET Inhibitor Onartuzumab in Patients with Metastatic Colorectal Cancer. |
|---|---|
| Authors: | Bendell JC; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, Tennessee, USA jbendell@tnonc.com., Hochster H; Yale School of Medicine, New Haven, Connecticut, USA., Hart LL; Sarah Cannon Research Institute/Florida Cancer Specialists, Fort Myers, Florida, USA., Firdaus I; Sarah Cannon Research Institute/Oncology Hematology Care, Cincinnati, Ohio, USA., Mace JR; Sarah Cannon Research Institute/Florida Cancer Specialists, St Petersburg, Florida, USA., McFarlane JJ; Sarah Cannon Research Institute/Virginia Cancer Institute, Richmond, Virginia, USA., Kozloff M; University of Chicago, Chicago, Illinois, USA., Catenacci D; University of Chicago, Chicago, Illinois, USA., Hsu JJ; Genentech Inc., South San Francisco, California, USA., Hack SP; Genentech Inc., South San Francisco, California, USA., Shames DS; Genentech Inc., South San Francisco, California, USA., Phan SC; Genentech Inc., South San Francisco, California, USA., Koeppen H; Genentech Inc., South San Francisco, California, USA., Cohn AL; Rocky Mountain Cancer Center, Denver, Colorado, USA. |
| Source: | The oncologist [Oncologist] 2017 Mar; Vol. 22 (3), pp. 264-271. Date of Electronic Publication: 2017 Feb 16. |
| Publication Type: | Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Oxford University Press Country of Publication: England NLM ID: 9607837 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1549-490X (Electronic) Linking ISSN: 10837159 NLM ISO Abbreviation: Oncologist Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
